A next-generation sequencing-based diagnostic test to identify any and every pathogen from a single sample
During a disease outbreak, an agnostic diagnostic (one that detects any pathogen) would be a powerful tool to help the public health response from day one. Next-generation sequencing (NGS) technologies can identify any pathogen present in a sample — including new pathogens. DRIVe is supporting the analytical and clinical validation of NGS-based agnostic diagnostic assays to bring this much-needed capability closer to commercialization for future pandemic preparation.
Companies we have partnered with on this program to date
DRIVe is starting with an NGS-based diagnostic that will cover all known and unknown respiratory RNA viruses. Partners will optimize their in-house NGS capabilities for commercial clinical use by:
A test that gives results within 24 hrs with sensitivity similar to molecular diagnostic assays
Assays designed for short and long-read sequencers
Clear regulatory strategies toward commercialization
BARDA's Division of Research, Innovation, and Ventures (DRIVe) is collaborating with multiple industry and academic partners to advance the ability to quickly respond to public health emergencies with a new...